Akero Therapeutics Past Earnings Performance

Past criteria checks 0/6

Akero Therapeutics's earnings have been declining at an average annual rate of -14.1%, while the Biotechs industry saw earnings growing at 12.7% annually.

Key information

-14.1%

Earnings growth rate

99.3%

EPS growth rate

Biotechs Industry Growth	17.0%
Revenue growth rate	n/a
Return on equity	-28.4%
Net Margin	n/a
Last Earnings Update	31 Dec 2023

Recent past performance updates

No updates

Recent updates

Akero Therapeutics (NASDAQ:AKRO) Is In A Good Position To Deliver On Growth Plans

Oct 01

Akero: Ticking All The Right Boxes In NASH

Sep 23

Akero Therapeutics (NASDAQ:AKRO) Is In A Good Position To Deliver On Growth Plans

Jun 10

Revenue & Expenses Breakdown
Beta

How Akero Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqGS:AKRO Revenue, expenses and earnings (USD Millions)
Date	Earnings	G+A Expenses	R&D Expenses
31 Dec 23	-152	31	142
30 Sep 23	-120	30	107
30 Jun 23	-116	33	93
31 Mar 23	-112	31	87
31 Dec 22	-112	30	85
30 Sep 22	-121	28	95
30 Jun 22	-110	21	89
31 Mar 22	-112	20	92
31 Dec 21	-101	19	82
30 Sep 21	-98	18	80
30 Jun 21	-95	18	78
31 Mar 21	-82	16	67
31 Dec 20	-79	15	65
30 Sep 20	-65	14	52
30 Jun 20	-59	13	49
31 Mar 20	-50	11	42
31 Dec 19	-44	9	37
30 Sep 19	-90	7	26
30 Jun 19	-86	5	13
31 Mar 19	-87	3	16
31 Dec 18	-82	2	12
30 Sep 18	-22	1	11

Quality Earnings: AKRO is currently unprofitable.

Growing Profit Margin: AKRO is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: AKRO is unprofitable, and losses have increased over the past 5 years at a rate of 14.1% per year.

Accelerating Growth: Unable to compare AKRO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AKRO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).

Return on Equity

High ROE: AKRO has a negative Return on Equity (-28.35%), as it is currently unprofitable.

Akero Therapeutics Past Earnings Performance

Past criteria checks 0/6

Key information

Recent past performance updates

Recent updates

Insufficient new directors

Akero Therapeutics Appoints Scott Gangloff as Chief Technology Officer

Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against Akero Therapeutics, Inc

Co-Founder notifies of intention to sell stock

Akero Therapeutics' EFX Data Warrants Caution

Akero Therapeutics, Inc. Announces Publication of Phase 2b SYMMETRY Cohort D Study in Clinical Gastroenterology and Hepatology

Akero Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $319 million.

President notifies of intention to sell stock

Akero Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $319 million.

Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study

Price target increased by 13% to US$48.38

Akero: Phase 2b NASH Data Bodes Well For Phase 3 SYNCHRONY Program

New major risk - Revenue and earnings growth

New minor risk - Share price stability

Akero Therapeutics, Inc. Announces First Patients Dosed in Efruxifermin Phase 3 Synchrony Program

President exercised options and sold US$368k worth of stock

Co-Founder recently sold US$440k worth of stock

Price target decreased by 29% to US$48.44

Akero Therapeutics, Inc. Reports Encouraging 36-Week Analysis of 96-Week Phase 2b SYMMETRY Study, with a Trend on Fibrosis Improvement and Statistically Significant Results for NASH Resolution, Markers of Liver Injury and Fibrosis, Insulin Sensitization and Lipoproteins

New major risk - Share price stability

Akero Therapeutics, Inc. to Present Results from Phase 2B Symmetry Study Investigating Efruxifermin in Patients with Compensated Cirrhosis Due to NASH

Akero Therapeutics, Inc. Announces Publication of the Harmony Phase 2B Trial Results in the Lancet Gastroenterology & Hepatology

President notifies of intention to sell stock

Price target increased by 7.3% to US$67.75

Price target increased by 7.7% to US$64.75

Insider notifies of intention to sell stock

Akero Therapeutics, Inc. to Report Results of Phase 2b SYMMETRY Study in October 2023

President exercised options and sold US$920k worth of stock

Co-Founder & Chief Scientific Officer notifies of intention to sell stock

Akero Therapeutics, Inc.(NasdaqGS:AKRO) dropped from Russell Small Cap Comp Value Index

Co-Founder & Chief Scientific Officer recently sold US$2.1m worth of stock

Co-Founder & Chief Scientific Officer notifies of intention to sell stock

President exercised options and sold US$1.1m worth of stock

Akero Therapeutics, Inc. Releases Topline Data from an Expansion Cohort of the Phase 2B SYMMETRY Study

President exercised options and sold US$1.1m worth of stock

President notifies of intention to sell stock

President exercised options and sold US$1.2m worth of stock

President exercised options and sold US$1.2m worth of stock

Insider notifies of intention to sell stock

Akero Therapeutics, Inc. Announces the Appointment of Patrick Lamy as Senior Vice President, Commercial Strategy

Co-Founder exercised options and sold US$544k worth of stock

Price target increased to US$52.00

Akero Therapeutics, Inc. Completes Enrollment of Phase 2B SYMMETRY Study

President exercised options and sold US$455k worth of stock

Independent Director recently sold US$1.1m worth of stock

President exercised options and sold US$428k worth of stock

Independent Director recently sold US$12m worth of stock

Price target increased to US$48.33

Co-Founder & Chief Scientific Officer exercised options and sold US$299k worth of stock

Akero Therapeutics announces closing of upsized public offering

President notifies of intention to sell stock

Akero Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $200.000008 million.

Akero Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $200.000008 million.

Akero Therapeutics, Inc. Releases Topline Data from HARMONY

Akero adds over 100% rallying peers after NASH success

Akero Therapeutics, Inc. Announces Results from Cohort C of its Phase 2a BALANCED trial in non-alcoholic steatohepatitis

Price target decreased to US$41.67

Akero Therapeutics Presents Analysis at the 2022 International Liver Congress Showing that Efruxifermin Improved Histopathology and Markers of Liver Injury Across PNPLA3 Genotypes in Patients with NASH Fibrosis

Akero Therapeutics, Inc. announced that it expects to receive $100 million in funding from Hercules Capital, Inc.

High number of new directors

We're Not Very Worried About Akero Therapeutics' (NASDAQ:AKRO) Cash Burn Rate

High number of new directors

President exercised options and sold US$170k worth of stock

Akero Therapeutics Completes Enrollment of Phase 2b HARMONY Study in Pre-Cirrhotic NASH Patients

President exercised options and sold US$169k worth of stock

Executive VP exercised options and sold US$146k worth of stock

We Think Akero Therapeutics (NASDAQ:AKRO) Can Afford To Drive Business Growth

President exercised options and sold US$189k worth of stock

Executive VP exercised options and sold US$99k worth of stock

Executive VP exercised options and sold US$98k worth of stock

Price target decreased to US$53.00

Akero Therapeutics (NASDAQ:AKRO) Is In A Good Position To Deliver On Growth Plans

Akero: Ticking All The Right Boxes In NASH

Executive VP exercised options and sold US$145k worth of stock

President notifies of intention to sell stock

Revenue & Expenses Breakdown
Beta